Product logins

Find logins to all Clarivate products below.


Nilotinib Hydrochloride

TASIGNA®

About TASIGNA®

  • Marketed by Novartis Pharmaceuticals Corporation
  • Orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor
  • Treatment of adult and pediatric patients with newly diagnosed or treatment-resistant Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

Review and approval status

November 19, 2007

First E.U. approval

October 29, 2007

First U.S. approval

Actual and expected launch:

  • 2023: Patent expiry: United States
  • 2023: Patent expiry: European Union
  • 2028: Patent expiry: Japan

API availability